Science Matters: Welcome To The Oncobiome

A new publication offers up proof of concept that the genetic signatures of microorganisms found in blood and tumor tissue could improve precision medicine cancer diagnostics. The study also bolsters the notion that targeting the microbiome could lead to innovative cancer therapies.

Science Matters

For the better part of the past decade, computational scientists have been using machine learning to “try to extract value and meaning from data sets that might otherwise be obscure,” in the words of Atul Butte, director of the University of California, San Francisco’s Bakar Computational Health Sciences Institute and chief data scientist for the University of California Health System. A group at the University of California, San Diego (UCSD) has now uncovered such an obscure – and valuable – data set from existing human cancer genomic studies, teasing out diagnostic information from microorganisms that reside inside cancer patients.

Taking sequencing data from samples deposited into The Cancer Genome Atlas (TCGA) project, the researchers showed that microbial signatures derived...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.